- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07612384
Effects of Abdominal Binder on Dysnea, Control Pause and Quality of Life in Asthmatic Patients
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Islamabad, Pakistan
- Foundation University Islamabad
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age :18 to 65
- Diagnosed asthma (persistent, not solely intermittent, seasonal, or exercise-induced).
- Mild to moderate asthma; > 2 days/week (not daily) Minor activity limitation* FEV₁ ≥80.
- Capable of performing dyspnea control pause (DCP) testing and completing QoL questionnaires.
- No recent hospitalization due to asthma.
Exclusion Criteria:
- Intermittent, seasonal-only, or exercise-induced asthma.
- Presence of other major respiratory diseases (COPD, bronchitis, pneumonia, fibro tic disorders)
- Severe comorbidity: cardiac arrhythmia, CHF, CAD, uncontrolled hypertension/diabetes, renal/hepatic
- Severe asthma (Symptoms all day Frequent night awakenings* FEV₁ <60% predicted.) ▪️ Unable to perform breathing exercises
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Experimental group abdominal binder-assisted diaphragmatic breathing exercises
This group will receive standard medical management for asthma along with abdominal binder-assisted diaphragmatic breathing exercises.
The abdominal binder will be used to provide external resistance and tactile feedback to the diaphragm.
The intervention will be conducted for 4 weeks ( supervised and home-based sessions).
Training intensity will progress from light resistance (Weeks 1-2) to high resistance (Weeks 3-4).
|
Participants perform slow, deep diaphragmatic inhalations and exhalations Mechanism: The abdominal binder is applied to increase intro-abdominal pressure, helping to reposition the flattened diaphragm in asthma patients into a more efficient, dome-like shape (zone of apposition).
Dosage: 4 weeks total; Progression: Intensity is increased by tightening the binder/increasing resistance over the final 2 weeks of the study.
|
|
Aktiv komparator: Control group conventional diaphragmatic breathing exercises
This group will receive standard medical management for asthma and perform conventional diaphragmatic breathing exercises alone without the use of an abdominal binder.
The frequency and duration will match the experimental group (for week for 4 weeks) to control for the effects of the breathing exercises themselves.
|
This group receives standard medical management for asthma and performs conventional diaphragmatic breathing exercises alone. Unlike the experimental group, these exercises are performed without the use of an abdominal binder. Frequency and Duration: The sessions are conducted 14 times per week for a total of 4 weeks. This matches the experimental group's schedule to ensure the results accurately control for the effects of the breathing exercises themselves. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dyspnea
Tidsram: 04 weeks
|
Dyspnea was assessed using the Dyspnea-12 Questionnaire, a validated self-administered instrument designed to measure the severity of breathlessness.
The questionnaire consists of 12 items that evaluate both the physical and affective components of dyspnea experienced by the participant.
Each item is scored on a 4-point Likert scale ranging from 0 (none) to 3 (severe), with a total score ranging from 0 to 36.
Higher scores indicate greater severity of dyspnea and a greater impact of breathlessness on daily functioning.
The Dyspnea-12 has demonstrated good reliability and validity for assessing multidimensional breathlessness across clinical populations
|
04 weeks
|
|
control pause (Breath- hold time )
Tidsram: 04 weeks
|
Control pause was assessed using the breath-hold time test, a measure commonly used to evaluate breathing pattern efficiency and carbon dioxide tolerance in individuals with Asthma.
Participants were instructed to sit comfortably and breathe normally for several breaths.
At the end of a normal exhalation, they were asked to gently hold their breath by pinching the nose until the first natural urge to breathe was experienced, such as diaphragmatic contraction or mild air hunger.
The breath-hold duration was recorded in seconds using a stopwatch.
Lower control pause values in asthma are often associated with dysfunctional breathing patterns, airway hyperresponsiveness, and poor symptom control, whereas higher values indicate improved respiratory regulation, greater carbon dioxide tolerance, and enhanced breathing efficiency.
|
04 weeks
|
|
Asthma-Related Quality of Life
Tidsram: 04 weeks
|
Asthma-related quality of life was assessed using the Asthma Quality of Life Questionnaire (AQLQ), a validated 32-item questionnaire designed to evaluate the impact of Asthma on daily functioning and well-being.
The questionnaire assesses four domains: symptoms, activity limitation, emotional function, and environmental stimuli.
Each item is scored on a 7-point Likert scale, with total scores ranging from 1 (severely impaired) to 7 (not impaired).
Higher scores indicate better quality of life, reflecting minimal impact of asthma on daily activities and overall well-being, whereas lower scores indicate poorer functional status, greater symptom burden, and significant lifestyle restriction due to asthma.
|
04 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- FUCP/CTR/2026/07
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .